转换医学在冠心病治疗中的应用课件.pptVIP

Thank You * * * Lecture Notes: If the TIMI-3 flow increased to 94%, then the mortality will be around 4.3% +/-1%, which is the mortality of the Stent-PAMI, ADMIRAL, or CADILLAC trials. The value of TIMI Grade 3 flow as a surrogate endpoint for mortality was demonstrated in the GUSTO 1 trial. The GUSTO 1 angiographic investigators demonstrated that the 22% improvement in TIMI Grade 3 Flow at 90 minutes of rt-PA (recombinant tissue plasminogen activator, tPA) over Streptokinase (SK) resulted in a 1.1% improvement in mortality. It has therefore been predicted that it would require a 20% improvement in the rate of TIMI grade 3 flow to yield a 1% improvement in mortality. Thus, this trial satisfies the criteria for a surrogate mortality endpoint: TIMI 3 flow is associated with improved mortality and changes in a reperfusion regimen that yield higher rates of TIMI 3 flow are associated with a lower mortality. Reference: 1. The GUSTO Angiographic Investigators. N Engl J Med. 1993;329:1615-1622. Lecture Notes: If the TIMI-3 flow increased to 94%, then the mortality will be around 4.3% +/-1%, which is the mortality of the Stent-PAMI, ADMIRAL, or CADILLAC trials. The value of TIMI Grade 3 flow as a surrogate endpoint for mortality was demonstrated in the GUSTO 1 trial. The GUSTO 1 angiographic investigators demonstrated that the 22% improvement in TIMI Grade 3 Flow at 90 minutes of rt-PA (recombinant tissue plasminogen activator, tPA) over Streptokinase (SK) resulted in a 1.1% improvement in mortality. It has therefore been predicted that it would require a 20% improvement in the rate of TIMI grade 3 flow to yield a 1% improvement in mortality. Thus, this trial satisfies the criteria for a surrogate mortality endpoint: TIMI 3 flow is associated with improved mortality and changes in a reperfusion regimen that yield higher rates of TIMI 3 flow are associated with a lower mortality. Reference: 1. The GUSTO Angiographic Investigators. N Engl J Med. 1993;329:1615-1622. * * *